… ProQR Announces Virtual Presentation at EURETINA 2021 LEIDEN, … & CAMBRIDGE, Mass., Sept. 06, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … on the EURETINA platform at the start of the congress. ProQR’s Presentation Title: Phase 1b/2 interim results of …
… ProQR Announces Expert Perspectives Conference Call Series … & CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Drs. Girach and Koenekoop will also discuss QR-421a, ProQR’s investigational therapy for patients with Usher …
… ProQR Announces Extraordinary General Meeting of Shareholders … be made available in the ‘Investor Relations’section of ProQR’s website ( www.proqr.com ) under ‘Financial Information’. The documents …
LEIDEN, Netherlands, Sept. 18, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics today announced the pricing of its initial public offering of 7,500,000 ordinary shares at an initial public offering price of $13.00 per ordinary share.
… ProQR to Present at Two Upcoming Conferences LEIDEN, the Netherlands, April 03, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … at 9:25 am CET, Daniel de Boer, Chief Executive Officer of ProQR, will present at the H.C. Wainwright Global Life …
… ProQR to Participate in Upcoming Investor Conferences LEIDEN, … & CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … 30 days following the presentation date. About ProQRProQR Therapeutics is dedicated to changing lives …
… ProQR Therapeutics Added to NASDAQ Biotechnology Index … & CAMBRIDGE, Mass., Dec. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … and share volume requirements among other criteria. About ProQRProQR Therapeutics is dedicated to changing lives …
… ProQR Announces Proposed Public Offering of Ordinary Shares … LEIDEN, the Netherlands, Nov. 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … public offering. All of the shares are being offered by ProQR. In addition, in the public offering, ProQR expects to …